Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors

NCT04617314 is registered in ClinicalTrials.gov with RemeGen Co., Ltd. as lead sponsor.

NCT NCT04617314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04617314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Effect of RC108-ADC For Injection in Subjects With c-Met Positive Advanced Malignant Solid Tumors
Lead sponsor
RemeGen Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 10, 2021
Completion date
December 31, 2025
Enrollment
67 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor